tirzepatide withdrawal Study shows that 82% saw weight rebound and cardiovascular health reverse after from taking GLP-1 drugs Weight regain and cardiometabolic effects

28-02-2024 Pilar Todo bien

These clinical data signaled the impending arrival of an expanding armamentarium of obesity medications

This combination preserves lean mass effectively during the weight loss phase

The last study published in 2024 by Zmitek et al

A phase II study also demonstrated that liraglutide treatment was associated with improvements in triglycerides in addition to reductions in plasminogen activator inhibitor-1 (PAI-1)

[18] showed that intravenous infusion of GLP-1 for 48 hours in animal models with induced dilated cardiomyopathy significantly improved LV contractility, stroke volume, and cardiac output